Genetic support for an adverse effect of calcium channel blockers on the human thoracic aorta
- 1Amsterdam UMC
Abstract
Despite the widespread use of L-type calcium channel blockers (CCBs), recent observational and murine functional work has suggested a potential adverse effect of this medication class on the aorta. Here, we apply a Mendelian randomization (MR) framework to assess the potential causal role of CACNA1C - the principal target of L-type CCBs in the human aorta - on thoracic aortic aneurysm and dissection (TAA/D). Genetic instrumental variables were derived from aortic expression quantitative trait locus data, and combined with large-scale genome-wide association data of TAA/D and ascending aortic diameter. Mirroring the on-target vascular effects of L-type CCBs, higher genetically predicted CACNA1C expression was linked to higher blood pressure, and to higher risks of hypertension and coronary artery disease. In contrast, higher predicted aortic expression of CACNA1C was linked to lower risk of TAA/D ({beta}=-0.18, P=0.005) and to a smaller ascending aortic diameter in the general population ({beta}=-0.08, P=0.005). While we caution against overinterpretation of our MR results in isolation, the convergence with observational and functional data calls for dedicated clinical trials to assess the safety of CCBs in the context of aortic disease.
Related
- Comparative Outcomes of Beta-Blockers vs Non-Dihydropyridine Calcium Channel Blockers in Heart Failure With Preserved Ejection Fraction: A Systematic Review and Meta-Analysis
- Comparative Cardiovascular Outcomes of Fimasartan and Calcium Channel Blockers in Hypertension: A Nationwide 3-Year Follow-Up Cohort Study
- Accelerated Systemic Atherosclerosis Following Immune-Related Adverse Events in a Patient with Primary Thoracic Melanoma: A Case of Sequential Coronary and Peripheral Revascularization
- Noninvasive respiratory support for adult patients with acute respiratory failure: an official American Thoracic Society Clinical Practice Guideline
- Associations of adverse childhood experiences and social support with gastrointestinal disease among middle-aged and older Chinese adults: an exploratory mediation analysis
BibTeX
@misc{horjus2026genetic,
title = {{Genetic support for an adverse effect of calcium channel blockers on the human thoracic aorta}},
author = {J. Horjus and S. J. Jurgens and C. R. Bezzina and N. Grewal},
howpublished = {medRxiv},
year = {2026},
month = oct,
doi = {10.64898/2026.10.02.26364570},
url = {https://www.medrxiv.org/content/10.64898/2026.10.02.26364570v1},
note = {CC BY-NC},
}
RIS
TY - UNPB
TI - Genetic support for an adverse effect of calcium channel blockers on the human thoracic aorta
AU - J. Horjus
AU - S. J. Jurgens
AU - C. R. Bezzina
AU - N. Grewal
PY - 2026
DA - 2026/10/02
PB - medRxiv
DO - 10.64898/2026.10.02.26364570
UR - https://www.medrxiv.org/content/10.64898/2026.10.02.26364570v1
AB - Despite the widespread use of L-type calcium channel blockers (CCBs), recent observational and murine functional work has suggested a potential adverse effect of this medication class on the aorta. Here, we apply a Mendelian randomization (MR) framework to assess the potential causal role of CACNA1C - the principal target of L-type CCBs in the human aorta - on thoracic aortic aneurysm and dissection (TAA/D). Genetic instrumental variables were derived from aortic expression quantitative trait locus data, and combined with large-scale genome-wide association data of TAA/D and ascending aortic diameter. Mirroring the on-target vascular effects of L-type CCBs, higher genetically predicted CACNA1C expression was linked to higher blood pressure, and to higher risks of hypertension and coronary artery disease. In contrast, higher predicted aortic expression of CACNA1C was linked to lower risk of TAA/D ({beta}=-0.18, P=0.005) and to a smaller ascending aortic diameter in the general population ({beta}=-0.08, P=0.005). While we caution against overinterpretation of our MR results in isolation, the convergence with observational and functional data calls for dedicated clinical trials to assess the safety of CCBs in the context of aortic disease.
ER -